Europe active pharmaceutical ingredients (API) market was valued at $ 49.4 billion in 2022 and will grow by 6.8% annually over 2022-2032, driven by rising adoption of biologics in disease management, ...

North America active pharmaceutical ingredients (API) market is projected to grow by 4.8% annually in the forecast period and reach $120.7 billion by 2032, driven by rising adoption of biologics in ...

The stock's fall snapped a three-day winning streak.

AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

CHENNAI: Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in Indian pharma/biotech innova ...

This was the stock's third consecutive day of gains.

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

Analysts have provided new insights into AbbVie and Esperion, two major players in the healthcare sector. AbbVie’s stock has ...